Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide
Completed
- Conditions
- Healthy
- Registration Number
- NCT00806013
- Lead Sponsor
- Chinese Academy of Sciences
- Brief Summary
The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.
- Detailed Description
Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 36
Inclusion Criteria
- nonsmokers and in good health
Exclusion Criteria
- family history of diabetes mellitus
- taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The second hospital to Liaoning University of TCM
🇨🇳Shenyang, Liaoning, China